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The objective of this study was to evaluate the utility of the determination of adenosine deaminase 
(ADA) level in pleural ﬂuid for the diﬀerential diagnosis between tuberculous pleural eﬀusion (TPE) 
and malignant pleural eﬀusion (MPE) in Japan,  a country with intermediate incidence of tuberculosis 
(TB).  We retrospectively reviewed the clinical records of 435 patients with pleural eﬀusion and inves-
tigated their pleural ADA levels as determined by an auto analyzer.  ROC analysis was also per-
formed.  The study included patients with MPE (n＝188),  TPE (n＝124),  benign nontuberculous pleural 
eﬀusion (n＝94),  and pleural eﬀusion of unknown etiology (n＝29).  The median ADA level in the TPE 
group was 70.8U/L,  which was signiﬁcantly higher than that in any other groups (p＜0.05).  The area 
under the curve (AUC) in ROC analysis was 0.895.  With a cut-oﬀ level for ADA of 36U/L,  the sensi-
tivity,  speciﬁcity,  positive predictive value,  and negative predictive value were 85.5ｵ,  86.5ｵ,  69.7ｵ,  
and 93.6ｵ,  respectively.  As many as 9ｵ of patients with lung cancer and 15ｵ of those with mesothe-
lioma were false-positive with this ADA cutoﬀ setting.  Although the ADA activity in pleural ﬂuid can 
help in the diagnosis of TPE,  it should be noted that some cases of lung cancer or mesothelioma show 
high ADA activity in geographical regions with intermediate incidence of TB,  in contrast to high 
prevalence areas.
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alignant diseases and tuberculosis (TB) are 
major causes of pleural eﬀusion,  and such 
pleural eﬀusions are usually exudative [1-3].  Massive 
pleural eﬀusion causes severe dyspnea due to progres-
sive respiratory failure,  and markedly aﬀects the 
prognosis of patients with either malignant disease or 
TB.  Therefore,  patients with pleural eﬀusion need to 
be promptly and accurately diagnosed and immediately 
treated.  However,  diﬀerentiating tuberculous pleural 
eﬀusion (TPE) from malignant pleural eﬀusion (MPE) 
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can be a critical problem.
　 Pleural ﬂuid cytology is the simplest,  most deﬁni-
tive method for diagnosing MPE.  The diagnostic yield 
is dependent on factors such as the extent of disease 
and the nature of the primary malignancy [2].  
Therefore,  previous studies have shown a large varia-
tion in diagnostic yields ranging from 60-90ｵ [2].  
The diagnostic yield of cytology for mesothelioma is 
30ｵ [1].
　 The diagnosis of TPE is usually made from histo-
logical conﬁrmation of granulomas in pleural biopsy 
specimens and/or detection of Mycobacterium tuberculo-
sis (M. tuberculosis) from pleural tissue or pleural ﬂuid.  
However,  the sensitivity of these methods is not suf-
ﬁciently high even if histological examination of a 
pleural biopsy specimen and culture of a pleural ﬂuid 
are combined [4,  5].  Although repeating these diag-
nostic procedures could yield more positive results,  
such an approach would place patients at higher risk 
of complications and cost more.  Accordingly,  a reli-
able clinical marker providing rapid and accurate 
diagnosis of TPE or MPE is urgently required 
[6-8].
　 An elevated level of adenosine deaminase (ADA) in 
pleural ﬂuid has been reported to predict TPE with a 
sensitivity of 90ｵ to 100ｵ and speciﬁcity of 89ｵ to 
100ｵ,  although such reports have been performed 
mainly in geographical regions with a high prevalence 
of TB [3,  9-14].  Although the ADA activity in 
pleural ﬂuid is frequently measured in Japan,  a coun-
try with intermediate prevalence of TB [15,  16],  the 
utility of this method for Japanese patients remains 
unclear.  In this study,  we retrospectively reviewed 
patients with pleural eﬀusion in our hospital and 
investigated the utility of determination of ADA activ-
ity for diﬀerential diagnosis between TPE and MPE.
Materials and Methods
　 This study was approved by the Institutional 
Review Board of the Yamaguchi-Ube Medical Center.  
Clinical records of 724 consecutive patients undergo-
ing thoracocentesis for pleural eﬀusion at Yamaguchi-
Ube Medical Center between January 1995 and 
December 2008 were retrospectively reviewed.  
Informed consent was received from all patients before 
thoracocentesis.  The ADA activity was measured in 
pleural ﬂuid of 435 patients by an auto analyzer using 
commercially available kits (Nittobo Medical,  Tokyo,  
Japan).  The utility of the measurement of ADA activ-
ity in pleural eﬀusion was evaluated for these 435 
patients.
　 Diagnostic criteria for pleural eﬀusions.
TPE was diagnosed by conﬁrming one of the 
following: isolation of M. tuberculosis from pleural ﬂuid 
or pleural tissue; detection of granulomas in the 
pleural tissue with positive staining for acid fast 
bacilli (AFB); or detection of granulomas in pleural 
tissue with observation of clinical response to antitu-
berculous treatment.  MPE was diagnosed either by 
cytological observation of malignant cells in pleural 
ﬂuid or histological conﬁrmation of malignancy in a 
pleural biopsy specimen.  MPE was also diagnosed 
after exclusion of other diseases,  if patients had 
widely disseminated cancer and the pleural eﬀusion 
was strongly suspected to be caused by the cancer [6,  
7,  17].
　 Statistical analysis. Group comparisons were 
made using the nonparametric Kruskal-Wallis test.  
The discriminating quality of ADA was evaluated 
independently using receiver operating characteristic 
(ROC) curve analysis [18].  The quality of the bio-
logical markers was assessed based on the area under 
the curve (AUC).  For each ROC curve,  a cut-oﬀ 
point was determined as the value of the parameter 
that maximized the sum of speciﬁcity and sensitivity,  
weighting their signiﬁcance equally.
Results
　 Characteristics of the reviewed cases. The 
patients consisted of 333 men and 102 women,  and the 
mean age was 69 years.  The most frequent cause of 
pleural eﬀusion was MPE (n＝188,  43.0ｵ),  followed 
by TPE (n＝124,  28.4ｵ),  parapneumonic pleural 
eﬀusion (n＝23,  5.3ｵ),  heart failure (n＝16,  3.7ｵ),  
asbestos-related pleural eﬀusion (n＝12,  2.7ｵ),  
bacterial pleuritis (n＝11,  2.5ｵ),  ﬁbrous pleuritis 
(n＝7,  1.6ｵ),  rheumatoid pleuritis (n＝7,  1.6ｵ),  
empyema (n＝4,  0.9ｵ),  renal failure (n＝3,  0.7ｵ),  
Meigsʼ syndrome (n＝2,  0.5ｵ),  nontuberculous myco-
bacterium (n＝2,  0.5ｵ),  pneumothorax (n＝2,  0.5ｵ),  
traumatic pleural eﬀusion (n＝2,  0.5ｵ),  aneurysm 
(n＝1,  0.2ｵ),  angitis (n＝1,  0.2ｵ),  liver cirrhosis 
(n＝1,  0.2ｵ),  malnutrition (n＝1,  0.2ｵ),  and pan-
creatitis (n＝1,  0.2ｵ).  In 29 cases (6.6ｵ),  the cause 
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of the eﬀusion could not be identiﬁed.
　 The most common tumor,  responsible for 78.7ｵ of 
MPE,  was lung cancer,  followed by mesothelioma 
(10.6ｵ),  breast cancer (2.7ｵ),  lymphoma (2.1ｵ),  
colon cancer (1.1ｵ),  gastric cancer (1.1ｵ),  hepa-
toma (1.1ｵ),  prostate cancer (0.5ｵ),  thymus cancer 
(0.5ｵ),  and uterus cancer (0.5ｵ).  In 2 cases (1.1ｵ),  
the primary sites were unknown.
　 ADA levels in pleural eﬀusion. The median 
values of ADA were 70.8U/L (10.3-182.6U/L) in 
patients with TPE,  19.0U/L (1.7-193.4U/L) in 
those with MPE,  17.8U/L (1.6-500U/L) in those 
with non-tuberculous/non-malignant pleural eﬀusion,  
and 22.8U/L (10.7-70.5U/L) in those without identi-
ﬁed causes (Fig.  1).  ADA levels in pleural eﬀusion 
were signiﬁcantly higher in patients with TPE than in 
patients of the other groups (p＜0.05).
　 Diagnostic utility for tuberculous pleural 
eﬀusion. In order to diﬀerentiate patients with 
TPE from those with eﬀusions due to other causes,  
the diagnostic value of the ADA level in pleural ﬂuid 
was assessed using a ROC analysis (Fig.  2).  The area 
under the curve was 0.895.  At the deﬁned cutoﬀ 
value of 36U/L,  the sensitivity,  speciﬁcity,  positive 
predictive value,  and negative predictive value were 
85.5ｵ,  86.5ｵ,  69.7ｵ and 93.6ｵ,  respectively.
　 ADA levels in nontuberculous pleural eﬀu-
sion. Of the 435 patients with pleural eﬀusion,  
152 patients (34.8ｵ) had a pleural ADA level over 
36U/L.  Of those,  106 patients had TPE and 46 had 
nontuberculous pleural eﬀusion,  which consisted of 18 
patients with MPE,  5 with pneumonic eﬀusions,  5 
with rheumatoid arthritis,  3 with asbestos pleurisy,  3 
with empyema,  3 with bacterial pleuritis,  2 with 
nontuberculous mycobacteria infection,  1 with aneu-
rysm,  1 with Meigs syndrome,  and 5 with eﬀusions 
without identiﬁed cause.
　 With regard to the ADA level of MPE (Fig.  3),  
13 of 148 patients with lung cancer (8.8ｵ),  3 of 20 
with mesothelioma (15ｵ),  1 with lymphoma and 1 with 
hepatoma had pleural eﬀusions with an ADA level 
over 36U/L.  In particular,  ADA levels in pleural 
ﬂuid were over 100U/L in 2 patients with lung cancer 
and 1 with mesothelioma.
Discussion
　 Pleural ﬂuid cytology is the simplest,  most deﬁni-
tive method for diagnosis of MPE.  The diagnostic 
yield is dependent on factors such as the stage of dis-
ease and the nature of the primary malignancy.  
Malignant eﬀusion can be diagnosed with one pleural 
ﬂuid cytology specimen for 60ｵ of cases of carcinoma 
but only 30ｵ of cases of mesothelioma [1,  2].  
Diﬀerential diagnosis between MPE and TPE 
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Fig. 1　 ADA levels in 435 patients with various etiologies.  The 
horizontal bars represent group medians.
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Fig. 2　 An ROC curve showing the sensitivity and 1-speciﬁcity 
values at various cutoﬀ values for ADA levels in pleural ﬂuid.
becomes a more critical problem when the pleural ﬂuid 
cytology shows negative results.
　 ADA is present in most cells of the organism and 
is associated with the proliferation and diﬀerentiation 
of lymphocytes,  especially T lymphocytes.  The con-
centration of ADA in these lymphocytes is inversely 
proportional to their degrees of diﬀerentiation [9].  
ADA has gained increasing attention as a diagnostic 
tool,  especially in countries where the prevalence of 
TB is high [9-14].  It achieves a high sensitivity 
(90ｵ to 100ｵ) and is inexpensive and easy to mea-
sure.  It is also used in Japan,  although the prevalence 
of TB is not particular high in that country [15,  16].  
In Japan,  the TB notiﬁcation (incidence) rate fell 20 
per 100,000 in 2007 and continued to decline,  reach-
ing 19.4 in 2008 [16].  Our study shows that the sen-
sitivity of pleural ﬂuid ADA for TPE was 85ｵ in a 
Japanese cohort,  which is lower than that in area with 
a high prevalence of TB.
　 Our study also showed that the ADA levels in 
nontuberculous pleural eﬀusions exceeded the cutoﬀ 
value for TPE in Japan more frequently than in areas 
with a high incidence of TB.  The most common under-
lying disease with pleural eﬀusion was malignancy 
(43ｵ),  which included lung cancer (79ｵ of malig-
nancy) and mesothelioma (8ｵ of malignancy).  Nine 
percent of lung cancer patients and 15ｵ of mesothe-
lioma patients showed higher levels of ADA in pleural 
eﬀusion than the cutoﬀ set for tuberculous eﬀusion.  
High levels of ADA have already been reported in 
nontuberculous conditions associated with pleural ﬂuid 
lymphocytosis,  including malignant conditions (e.g.,  
adenocarcinoma,  mesothelioma,  leukemia,  and lym-
phomas) and collagen vascular disease (e.g.,  rheuma-
toid pleuritis and systemic lupus erythematosus) [9,  
19].  To our knowledge,  however,  the previous 
reports have been mainly case reports,  while this 
study has shown the frequency of patients with a high 
level of pleural ﬂuid ADA in malignant pleural eﬀu-
sions by a larger scale analysis.
　 At least 50ｵ of the cases of TB pleural eﬀusion 
are present as a primary disease without TB involve-
ment in other organs [20].  The patients with early 
stage mesothelioma and some with peripheral lung 
cancer show only pleural eﬀusions before forming 
obvious mass lesions.  Although mesothelioma is cur-
rently rare in Japan,  the incidence is rapidly increas-
ing [21,  22].  Since mesothelioma in the early stage 
may be curable by surgery,  accurate and prompt 
diagnosis of mesothelioma is very important [23].  
Accordingly,  other useful markers together with ADA 
are necessary for diagnosis of pleural eﬀusion.  A 
higher rate of false-positive results can lead to the 
unnecessary administration of antituberculous therapy 
or delay in making a precise diagnosis.  Indeed,  2 
patients with mesothelioma in this series were initially 
treated with antituberculous drugs,  and so the diagno-
sis of the cause of pleural eﬀusions was delayed.  
Their ﬁrst cytology tests were negative,  and the lev-
els of ADA in their pleural eﬀusions were high.  
Several monthsʼ treatment could not improve the eﬀu-
sion and the pleurae grew thicker,  and ﬁnally pleural 
biopsies revealed the diagnosis of mesothelioma.
　 The signiﬁcance of a high level of ADA in the 
pleural ﬂuid of malignant eﬀusion is not clear yet.  It 
might be associated with the parapneumonic eﬀusion 
caused by lung cancer-induced obstructive pneumonia 
or with the activity of lymphocytes during the immune 
reaction against tumors.  In this series,  a high level of 
pleural ﬂuid ADA did not aﬀect the survival of 
patients with malignant pleural eﬀusion (data not 
shown).  In practice,  a high level of ADA in pleural 
ﬂuid may lead to treatment for TPE,  as was the case 
in our mesothelioma patients.  It may occur that 
patients with lung cancer or mesothelioma are infected 
with TB concurrently.
　 In conclusion,  although the determination of the 
level of ADA in pleural ﬂuid can contribute to the 
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Fig. 3　 ADA levels in patients with malignant pleural eﬀusions.
diagnosis of TPE,  ADA should be used carefully for 
the diﬀerential diagnosis between TPE and MPE in 
Japan,  especially in the cases in which pleural eﬀusion 
is the sole manifestation.
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